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(HR=0.39; 95% CI 0.17-0.93, p=0.034) and OS (HR=0.32; 95% CI 
0.12-0.82, p=0.017). 
Conclusions: A high level of telomerase expression in tumoral tissue 
is strongly associated with increased risk of recurrence and mortal-
ity in resected NSCLC. The level of hTERT mRNA would predict the 
prognosis of lung cancer patients. 
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Purpose: According to the TNM staging system, atelectasis (At) is 
considered a bad prognostic factor within the T category. According 
to our clinical experience we intuitively considered the opposite. The 
aim of the study was to evaluate the inﬂuence of atelectasis on patient 
outcome for unresectable stage III and IV (NSCLC).
Patients and Methods: We prospectively evaluated the median 
progression free (PFS) and overall survival (MS), for the patients with 
pathologically/ citologically proven NSCLC, in relation with the pres-
ence or absence of the atelectasis. The treatment consisted of sequential 
chemo-radiation for stage III and platinum based combination chemo-
therapy with palliative irradiation for stage IV (PS:0-1). A preplanned 
analysis according to stage was foreseen.
Results: a number of 1352 consecutively treated patients, during 
1997-2004, were evaluated. Overall, we identiﬁed a number of 68 (5%) 
patients with atelectasis, 46/592 patients with stage III and 22/760 stage 
IV, ratio sex M/F: 1108 (82%)/172 (17.5%), age range 23-82 (median 
age 57 years), histology: adenocarcinoma: 419 (31%), squamous cell: 
327 (24%), undifferentiated: 127 (9.5%), other types: 31 (2.5%) and 
cytology: 448 (33%).
The median PFS and OS for patients with and without atelectasis are 
presented in table below. 
  No. Pat. PFS (m) p OS (m) p 2ys Sv
   95% CI  95% CI   
St III (592) At + 46 19 .0001 24 .0001 57%
(43.7%)   (11.22-25.78)  (18.65-29.35)   
 At - 546 8  14  13.5%
   (6.98-9.02)  (12.43-15.57)   
St IV (760) At + 22 8 .1046 16 .1451 19%
(56.3%)   (5.80-10.20)  (4.49-27.51)   
 At - 738 6  9  4%
   (5.53 -6.47)  (8.61-9.39)   
Total At + 68 16 <.0001 21  38%
   (11.19-20.81)  (12.37-29.63)   
 At - 1284 7  10  9.5%
   (6.53-7.47)  (9.48-10.52)   
Conclusion: Atelectasis predicts for better PFS and OS in patients with 
advanced NSCLC. The subset analysis showed a statistically signiﬁcant 
improved PFS and OS for unresectable stage III. For stage IV there is 
also a trend towards improved survival but statistically not signiﬁcant. 
The biologic impact of this clinical aspect in NSCLC should be further 
evaluated.
The multivariate analysis (including, age, sex, histology, RT, stage, 
type of chemotherapy) showed a statistically signiﬁcant independent 
prognostic value for atelectasis for stage III, but not in stage IV.
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Purpose: Aberrant methylation of CpG islands in promoter regions 
of tumor cells is one of the major mechanisms for silencing of tumor 
suppressor genes. Chromosome 3p is deleted frequently in lung cancer. 
The RAS association domain family 1A (RASSF1A) gene was isolated 
from the 3p21.3 region homozygously deleted in lung cancer cell lines, 
and it was shown to be inactivated by hypermethylation of the promoter 
region in lung cancers. In this study, we investigated the clinicopatho-
logical signiﬁcances of RASSF1A methylation in the development and/
or progression of small-sized (less than 2.0cm) lung adenocarcinoma. It 
is important to identify a marker for high-risk early stage patients who 
should beneﬁt from new investigational adjuvant therapies.
Methods: Surgically resected specimens from 260 primary lung adeno-
carcinoma 77 cases of small-sized adenocarcinoma. We determined the 
frequency of aberrant promoter methylation of the RASSF1A genes in 
77 small-sized lung adenocarcinoma. Aberrant promoter methylation 
was examined using methylation-speciﬁc PCR (MSP).
Results: Twenty-ﬁve of 77 (32.5%) tumors showed RASSF1A 
methylation. RASSF1A methylation was dominantly detected in 
smoker (p<0.03). There was no signiﬁcant correlation of RASSF1A 
methylation with gender, age, T stage, N stage and pathological stage. 
RASSF1A methylation correlated with adverse survival by univari-
ate analysis (p<0.005; log-rank test) as well as multivariate analysis 
(p=0.0062; risk ratio 4.251; 95% conﬁdence interval, 1.507-11.993). 
Furthermore, RASSF1A promoter hypermethylation in resected stage I 
small-sized lung adenocarcinoma was associated with impaired patient 
survival (p<0.01).
Conclusion: Aberrant promoter methylation of the RASSF1A was 
present in 25 of 77 (32.5%) of small-sized lung adenocarcinoma by 
MSP assay. These results indicated that epigenetic inactivation of 
RASSF1A plays an important role in the progression of small-sized 
lung adenocarcinoma, and that RASSF1A hypermethylation appears to 
be a useful molecular marker for the prognosis of patients with small-
sized and stage I lung adenocarcinoma.
Clinical Implications: RASSF1A is a potential tumor suppressor gene 
that undergoes epigenetic inactivation in lung adenocarcinoma through 
hypermethylation of its promoter region. RASSF1A methylation was 
signiﬁcantly related to unfavorable prognosis in small-sized lung 
adenocarcinoma.
